AxoGen, Inc. (AXGN)
AXGN Price and Sentiment
AXGN Latest news
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
2021-11-04 07:00ALACHUA, Fla. and TAMPA, Fla., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, chairman, CEO and president, will present at the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 17, 2021 at 4:25 p.m. (11:25 a.m. ET).
AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript
2021-11-03 21:09AxoGen's (AXGN) CEO Karen Zaderej on Q3 2021 Results - Earnings Call Transcript
AxoGen (AXGN) Reports Q3 Loss, Misses Revenue Estimates
2021-11-03 18:22AxoGen (AXGN) delivered earnings and revenue surprises of 25.00% and -9.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Axogen: Q3 Earnings Insights
2021-11-03 16:41Axogen (NASDAQ:AXGN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.
Axogen, Inc. Reports 2021 Third Quarter Financial Results
2021-11-03 16:01ALACHUA, Fla. and TAMPA, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the third quarter ended September 30, 2021.
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2021-10-27 16:12AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
2021-10-13 07:00ALACHUA, Fla. and TAMPA, Fla., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced that it will report third quarter 2021 financial results on Wednesday, November 3, 2021 after the market closes. Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.
Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
2021-09-22 07:00Industry leading nerve repair surgeons will share best practices and case studies during symposium session Industry leading nerve repair surgeons will share best practices and case studies during symposium session
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
2021-09-01 07:00RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company's Biologics License Application (BLA) for Avance® Nerve Graft
Axogen: Renewed Covid-19 Worries Hitting, But The Growth Story Is Very Appealing
2021-08-25 06:28Axogen continues posting double-digit growth in volumes against 2019 levels despite trauma, breast recon, and oral-maxillofacial procedures still well below pre-pandemic levels.